Item 8.01 section not located in normalized markdown

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **January
13, 2025**

**ENZO BIOCHEM, INC.**

(Exact name of registrant as specified in its charter)

New York |
001-09974 |
13-2866202 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |

**21 Executive Blvd. **

**Farmingdale, New York 11735**

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area
code: **(631) 755-5500**

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |
Trading Symbol(s) |
Name of each exchange on whichregistered | ||
| Common Stock, par value $0.01 per share | ENZ | The New York Stock Exchange |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

**Item 8.01 Other Events.**

On January 13, 2025, Enzo Biochem, Inc. (the “Company”) entered
into a Class Action Settlement Agreement and Release (the “Settlement Agreement”) for the settlement of the consolidated class
action civil suit against the Company, *In re Enzo Biochem Data Security Litig., *2:23-4282 (the “Consolidated Action”).
The Consolidated Action was initiated in regards to the ransomware attack that the Company suffered in April 2023, as previously disclosed
in the Company’s public filings.

The Settlement Agreement provides for the full and final release of the Company and its subsidiaries from any and all claims that were asserted in or could have been asserted in the Consolidated Action in exchange for (i) the establishment of a settlement fund by the Company in the amount of $7,500,000, an amount equal to the amount already accrued in relation to the Consolidated Action in the Company’s financial statements as of October 31, 2024 and (ii) the Company’s commitment to make certain upgrades to its data protection systems, which have been made. The effectiveness of the Settlement Agreement is subject to the approval of the District Court for the United States, Eastern District of New York.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC. |
| By: | /s/ Patricia Eckert | ||
| Name: | Patricia Eckert | ||
| Title: | Chief Financial Officer | ||
| Date: January 15, 2025 | |||